Mirum Pharmaceuticals to Announce Volixibat Primary Sclerosing Cholangitis VISTAS Study Results on May 4, 2026

Mirum Pharmaceuticals will host an investor call on May 4, 2026, to share the topline results from their VISTAS study of Volixibat in patients with primary sclerosing cholangitis. The company plans to release the findings from this study during the call.

The investor call will focus on the outcomes of the VISTAS study, which evaluated the effects of Volixibat on individuals diagnosed with primary sclerosing cholangitis. Primary sclerosing cholangitis is a chronic disease that affects the bile ducts. Investors and interested parties can anticipate a detailed presentation of the study’s key data points and findings during the call.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: May 3, 2026

Author

GOAI